Trials / Completed
CompletedNCT03235544
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 162 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, open-label, 2-cohort study designed to evaluate the efficacy and safety of 2 parsaclisib treatment regimens in participants with relapsed or refractory mantle cell lymphoma (MCL) previously treated either with or without a Bruton's tyrosine kinase (BTK) inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Parsaclisib | Parsaclisib tablets administered orally with water and without regard to food. |
Timeline
- Start date
- 2017-11-20
- Primary completion
- 2024-04-30
- Completion
- 2024-04-30
- First posted
- 2017-08-01
- Last updated
- 2025-03-18
- Results posted
- 2022-02-10
Locations
103 sites across 11 countries: United States, Belgium, Czechia, Denmark, France, Germany, Israel, Italy, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03235544. Inclusion in this directory is not an endorsement.